Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1784-1788

  Bobbio Pallavicini, E ^a,d   Porta, C ^b   Moroni, M ^b   Bertulezzi, G ^c   Civelli, L ^c   Pugliese, P ^b   Nastasi, G ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Ospedale Pesenti Fenaroli   (Italy)

^d NONE

Author keywords

Chemotherapy; Epirubicin; Hepatoma; Phase II study; Unresectable disease; VP 16

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031424749     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00163-9     Document Type: Article

References (2)

1. The Liver Study Group of Japan. Primary Liver Cancer in Japan (ninth report), 1990.
2. Epirubicin. In: Dorr RT, Von Hoff DD. Cancer Chemotherapy Handbook. Norwalk, Connecticut, Appleton & Lange, 1994, 434-439.